B and T cells in chronic graft-versus-host disease and graft-versus-leukemia - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 308

Table 14.1 Approaches to Improving Transplant Outcomes
cGVHD Treatment

Nonspeciicimmunesuppression
Corticosteroids
Cyclosporin
Tacrolimus
Mycophenolatemofetil
Sirolimus
Alemtuzumab
Extracorporealphotophoresis
B-cell-directedtherapy
Rituximab
Anti-BAFFtherapies
RegulatoryT-cellexpansion
In vivo: low-doseIL-2
Ex vivo: adoptivetherapywithdonorTregs
Platelet-derivedgrowthfactorreceptorinhibitionbyimatinib

312

Table 14.2 Approaches to Improving Transplant Outcomes
GVL/GVT Enhancement

AdoptiveT-celltherapy
Donorlymphocyteinfusion
Selectionofspeciiclymphocytesubsets
Nonspeciicexpansionofactivatedlymphocytes
Infusionofalloantigen-speciicTcells
ChimericantigenreceptordonorTcells
Tumor-speciicvaccines
Whole-tumorvaccines
Mutatedtumorantigenvaccines
Tumor-speciicpeptides
Immuneadjuvants
GM-CSF
Toll-likereceptoragonists
CD40ligand

Treatment of cGVHD

Over the past few decades of transplantation, there has been little progress
in the treatment of cGVHD. With the improvements in our understanding
of the pathogenesis of this disease and the kinetics of immune interactions,
and the generation of the NIH Working Group Consensus Statement for the
universal staging of cGVHD, we are in a position now to effectively test new
drugs, both individually and in combination. Ongoing clinical trials and
clinical trials in development are expected to result in real progress with
regard to this disease ( Table 14.1 ).